539730 Stock Overview
Manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, CIS countries, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Fredun Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹737.35 |
| 52 Week High | ₹1,054.00 |
| 52 Week Low | ₹650.00 |
| Beta | 1.32 |
| 1 Month Change | 9.45% |
| 3 Month Change | -2.60% |
| 1 Year Change | -15.46% |
| 3 Year Change | -15.47% |
| 5 Year Change | 227.27% |
| Change since IPO | 5,798.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 539730 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.3% | 0.6% | -4.2% |
| 1Y | -15.5% | 40.2% | 19.4% |
Return vs Industry: 539730 underperformed the Indian Pharmaceuticals industry which returned 40.2% over the past year.
Return vs Market: 539730 underperformed the Indian Market which returned 19.4% over the past year.
Price Volatility
| 539730 volatility | |
|---|---|
| 539730 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 539730 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 539730's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 256 | Daulat Medhora | www.fredungroup.com |
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, CIS countries, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It provides surgical products, such as IV fluids and cannula, disposable syringes, infusion sets, surgical gloves and cottons, and personal healthcare products; APIs; direct compressible granules; pellets; animal healthcare products; aqua products; and niche products.
Fredun Pharmaceuticals Limited Fundamentals Summary
| 539730 fundamental statistics | |
|---|---|
| Market cap | ₹3.46b |
| Earnings (TTM) | ₹176.89m |
| Revenue (TTM) | ₹3.90b |
19.6x
P/E Ratio0.9x
P/S RatioIs 539730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 539730 income statement (TTM) | |
|---|---|
| Revenue | ₹3.90b |
| Cost of Revenue | ₹3.03b |
| Gross Profit | ₹869.02m |
| Other Expenses | ₹692.13m |
| Earnings | ₹176.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 37.64 |
| Gross Margin | 22.27% |
| Net Profit Margin | 4.53% |
| Debt/Equity Ratio | 104.8% |
How did 539730 perform over the long term?
See historical performance and comparisonDividends
0.09%
Current Dividend Yield2%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 23:33 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fredun Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|